HOB BIOTECH(SH:688656)2022-04-24 16:00Financial Performance - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 20% growth compared to the previous year[153]. - The company's operating revenue for 2021 was CNY 31,770.75 million, representing a 43.20% increase compared to 2020[20]. - The net profit attributable to shareholders for 2021 was CNY 8,619.27 million, a growth of 52.24% year-over-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 7,330.54 million, up 71.49% from the previous year[20]. - The basic earnings per share for 2021 was CNY 1.40, reflecting a 16.67% increase compared to 2020[21]. - The company's total assets at the end of 2021 were CNY 86,391.93 million, a 191.46% increase from the end of 2020[20]. - The cash flow from operating activities for 2021 was CNY 10,479.28 million, representing a 79.98% increase compared to 2020[20]. - The company achieved total revenue of 317.71 million RMB, representing a year-on-year growth of 43.20%[103]. - The net profit attributable to the parent company was 86.19 million RMB, reflecting a year-on-year increase of 52.24%[103]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5.3 RMB per 10 shares, totaling approximately 33.42 million RMB, which represents 38.77% of the net profit attributable to shareholders for the year 2021[5]. - The company will carry forward the remaining undistributed profits to the next fiscal year[5]. - The company has a structured cash dividend policy that aligns with its long-term development strategy and shareholder interests[179]. Research and Development - The company invested 10.00% of its operating revenue in research and development in 2021[21]. - The total R&D investment for the year reached 31.72 million yuan, a 31.72% increase from the previous year, representing 10% of total revenue[74][75]. - The company has increased its R&D personnel from 62 to 81, with total R&D compensation rising from 12 million RMB to approximately 17.3 million RMB, indicating a commitment to enhancing its research capabilities[86]. - The R&D department is structured to focus on innovation and product quality improvement, with a new department dedicated to autoimmune product development[50]. - The company is focusing on expanding its product offerings in the autoimmune disease testing market, with ongoing projects aimed at improving detection capabilities[78]. Market Expansion and Strategy - The company projects a revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[13]. - The company is expanding its market presence in Europe, aiming to increase its market share by 15% over the next two years[15]. - Market expansion plans include entering three new international markets, projected to contribute an additional $100 million in revenue over the next two years[153]. - A strategic acquisition is planned to enhance the company's product portfolio and strengthen its competitive position in the immunodiagnostic market[12]. Product Development and Innovation - New product developments include the launch of the "Nabok" brand, which utilizes advanced nanomagnetic chemiluminescence technology for higher sensitivity and faster results[14]. - The company has launched a total of 80 food-specific IgG antibody test kits, targeting common food allergens[42]. - The company has developed an enzyme-linked immunoassay product for allergen IgE testing that can detect up to 21 allergens simultaneously, significantly improving testing efficiency and accuracy[70]. - The company has successfully developed multiple allergen detection products, leading the domestic market in the number of specific IgE allergens tested[70]. Operational Risks and Governance - The company has identified various operational risks in its annual report, which are detailed in the "Management Discussion and Analysis" section[4]. - The company has not violated decision-making procedures in providing guarantees to external parties[7]. - The company has established a clear decision-making process involving the shareholders' meeting, board of directors, and supervisory board[146]. - The company adheres to corporate governance standards as per the Company Law and relevant regulations, establishing a robust governance structure[146]. Environmental Responsibility - The company emphasizes environmental protection and sustainable development, adhering to local environmental laws and investing in pollution control measures[189]. - The company has established an environmental monitoring plan, commissioning qualified third parties annually to monitor emissions, with results meeting national standards[197]. - Environmental protection expenditure for 2021 amounted to 716,200 RMB, an increase from 699,100 RMB in 2020, 635,600 RMB in 2019, and 508,800 RMB in 2018[198]. - The company has received no administrative penalties related to environmental issues during the reporting period[199]. Employee Development and Management - The company has implemented a performance-based compensation system, linking bonuses to quarterly and annual assessments, with a focus on retaining core talent[177]. - The total number of employees in the parent company and major subsidiaries is 431, with 239 in the parent company and 192 in subsidiaries[175]. - The company completed 1,618 internal training sessions and 162 external training sessions in 2021, enhancing employee capabilities[178]. - The company has established a high-level talent team to support its development plans[144].